Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. ARS Pharmaceuticals, Inc. is another best biotech stock under $10 to buy.

TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform rating and a $25 price target. The firm highlighted Neffy, a needle-free intranasal epinephrine therapy, as a key innovation addressing long-standing challenges associated with injectable epinephrine use. It expects adoption to be supported by both new patient prescriptions and switching from existing injectable treatments, driven by improved ease of use and accessibility.

Linked to that, on March 27, the U.S. FDA approved an update to the prescribing information for neffy 1 mg (epinephrine nasal spray), removing prior age restrictions and allowing use in all patients weighing at least 33 lbs for emergency treatment of type 1 allergic reactions, including anaphylaxis.

The previous requirement limiting use to children aged four and older was eliminated. The revised labeling also provides updated instructions on storage and handling, recommending that patients keep the product in its blister pack or designated carrying case, with the company distributing a free case designed for two devices and planning to include it in future cartons. Additional FDA changes clarified dosing guidance related to accidental sniffing after administration, allowed use after freezing once thawed, and permitted short-term exposure to higher temperatures. The product is available in two strengths, with dosing based on patient weight categories for children and adults.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including an intranasal epinephrine product designed for rapid, needle-free emergency use.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.